

Christopher Brightling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11021555/publications.pdf>

Version: 2024-02-01

19
papers

5,428
citations

567144

15
h-index

839398

18
g-index

20
all docs

20
docs citations

20
times ranked

6224
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376.	2.7	7
2	Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents. <i>Chest</i> , 2020, 158, 68-96.	0.4	36
3	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. <i>European Respiratory Journal</i> , 2019, 54, 1900900.	3.1	56
4	Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. <i>European Respiratory Journal</i> , 2019, 54, 1900930.	3.1	28
5	Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations. <i>New England Journal of Medicine</i> , 2018, 378, 902-910.	13.9	119
6	Fevipirant in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 199-207.	1.9	23
7	Asthma. <i>Lancet, The</i> , 2018, 391, 783-800.	6.3	1,105
8	Pathogenesis of asthma: implications for precision medicine. <i>Clinical Science</i> , 2017, 131, 1723-1735.	1.8	118
9	Airway smooth muscle NOX4 is upregulated and modulates ROS generation in COPD. <i>Respiratory Research</i> , 2016, 17, 84.	1.4	35
10	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. <i>European Respiratory Journal</i> , 2016, 48, 92-103.	3.1	46
11	Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 607-617.	1.0	8
12	Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1595-1597.e7.	1.5	36
13	STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma. <i>Clinical Investigation</i> , 2015, 5, 701-711.	0.0	15
14	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 43, 343-373.	3.1	2,898
15	Lung function decline and variable airway inflammatory pattern: Longitudinal analysis of severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 287-294.e5.	1.5	58
16	A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. <i>European Respiratory Journal</i> , 2013, 41, 330-338.	3.1	334
17	Airway Hyperresponsiveness: Inflammatory Mechanisms and Clinical Aspects. , 2009, , 203-226.		0
18	Airway hyperresponsiveness is dissociated from airway wall structural remodeling. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 335-341.e3.	1.5	110

#	ARTICLE	IF	CITATIONS
19	Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. <i>Thorax</i> , 2007, 62, 1043-1049.	2.7	396